

Archives of Disease in Childhood

Lymphocyte subpopulations in premature infants: An observational study

Journal:	<i>Archives of Disease in Childhood</i>
Manuscript ID	fetalneonatal-2015-309246.R3
Article Type:	Original article
Edition:	not in use
Date Submitted by the Author:	n/a
Complete List of Authors:	Kent, Alison; St George's, University of London, Paediatric Infectious Diseases Research Group and Vaccine Institute Scorrer, Tim; Portsmouth Hospitals NHS Trust, Neonatal Unit Pollard, Andrew; University of Oxford, Oxford Vaccine Group; NIHR Oxford Biomedical Research Centre, Snape, Matthew; University of Oxford, Oxford Vaccine Group Clarke, Paul; Norfolk and Norwich University Hospitals NHS Foundation Trust, Neonatal Unit Few, Karen; Norfolk and Norwich University Hospitals NHS Foundation Trust, Neonatal Unit Menson, Esse; Evelina London Children's Hospital, Department of Paediatric Infectious Diseases Varghese, Anu; Royal Manchester Children's Hospital, Department of Paediatric Allergy and Immunology Hughes, Stephen; Royal Manchester Children's Hospital, Department of Paediatric Allergy and Immunology Ladhani, Shamez; Public Health England, Immunisation, Hepatitis and Blood Safety Department; St George's, University of London, Paediatric Infectious Diseases Research Group and Vaccine Institute Heath, Paul; St George's, University of London, Paediatric Infectious Diseases Research Group and Vaccine Institute
Keywords:	Neonatology, Immunology, Infectious Diseases

SCHOLARONE™
Manuscripts

Title page

**Lymphocyte subpopulations in premature infants:
An observational study**

Authors:

Kent, Alison (1)
Scorrer, Tim (2)
Pollard, Andrew J (3)
Snape, Matthew D (3)
Clarke, Paul (4)
Few, Karen (4)
Menson, Esse (5)
Varghese, Anu S (6)
Hughes, Stephen (6)
Ladhani, Shamez N (1, 7)
Heath, Paul T (1)

Author Affiliations:

1. Paediatric Infectious Diseases Research Group and Vaccine Institute, St George's, University of London, London, UK
2. Neonatal Unit, Queen Alexandra Hospital, Portsmouth, UK
3. Oxford Vaccine Group, University of Oxford, and the NIHR Oxford Biomedical Research Centre, Oxford UK
4. Neonatal Unit, Norfolk and Norwich University Hospitals NHS Foundation Trust, Norwich, UK
5. Department of Paediatric Infectious Diseases, Evelina London Children's Hospital, London, UK
6. Department of Paediatric Allergy and Immunology, Royal Manchester Children's Hospital, Manchester, UK
7. Immunisation, Hepatitis and Blood Safety Department, Public Health England, Colindale, London, UK

Corresponding author:

A Kent, Paediatric Infectious Diseases Research Group and Vaccine Institute, St George's, University of London, London, UK. alisonkent@doctors.org.uk

Abbreviations:

CD Cluster of differentiation
CI Confidence interval
CLD Chronic lung disease
NHS National Health Service
NK Natural killer
PBMC Peripheral blood mononuclear cell

Key words:

Infant, premature
Lymphocytes
Gestational Age
Lymphocyte subsets

Title page

Clinical trial registration: EudraCT number 2007-007535-23

Word count: 2463

Confidential: For Review Only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Manuscript

ABSTRACT

Background and objectives

The infant's immune system evolves over the first months and years of life. Strong positive correlation exists between lymphocyte count, lymphocyte subpopulations and gestational age at birth. Associations with antenatal and postnatal steroid treatment, infection and chronic lung disease have also been described. Few published studies report the effect of increasing postnatal age (PNA) and comorbidities on lymphocyte subpopulations in premature infants beyond the first 4 months of life. This study aimed to describe changes in lymphocyte subpopulations in preterm infants up to 13 months PNA.

Methods

Premature infants (23-34 weeks completed gestation) from 5 centres had lymphocyte subpopulations measured at 2, 5 or 7, 12 and 13 months PNA alongside their vaccine responses in a vaccination trial.

Results

393 blood samples from 151 babies were analysed. There was an increase in absolute numbers of total lymphocytes (median cell count $6.21 \times 10^9/L$ at 13 months compared with $4.9 \times 10^9/L$ at 2 months PNA) and $CD3^+$, $CD4^+$, $CD8^+$, natural killer and B cells with increasing age. At 2 months PNA there was a positive correlation between gestation and $CD3^+$ and $CD4^+$ counts ($r=0.32$ and 0.46 respectively) and proportions ($r=0.22$ and 0.41 respectively), and $CD4^+:CD8^+$ ratios ($r=0.57$) but a negative correlation with $CD8^+$ proportions ($r=-0.32$).

Conclusions

This longitudinal study describes the distribution of lymphocyte subpopulations in premature infants and provides reference ranges for the major lymphocyte subsets to help guide clinicians when assessing premature infants for immunodeficiency in the first year of life.

Manuscript

INTRODUCTION

Infection is a leading cause of morbidity and mortality in young infants and especially in those born prematurely [1–3]. Lymphocytes are key to the development of adaptive immunity and there are major changes in their numbers and function in term infants over the first year of life [4,5]. Reference ranges for lymphocyte counts and subpopulations exist for term infants and describe an increase in absolute counts in most lymphocyte subsets over the first 6 months of life [6,7].

Several studies have explored the effect of gestational age on lymphocyte subpopulations at birth [8–17]. Overall these studies show increasing concentrations of CD3⁺, CD4⁺, natural killer (NK) and B cells with increasing gestation.

Factors other than gestational age may affect lymphocyte subset populations. The use of antenatal steroids, for example, has been associated with increased cord blood T cells together with diminished T cell proliferation [11,13,18,19].

Few studies have described the changes in lymphocyte subpopulations after birth in premature infants who may have several months of ex-utero life before reaching term equivalent. Lymphocytes in these babies are likely to be influenced by both the infants' in-utero condition and their subsequent postnatal course. Existing studies have included only a small numbers of babies and have limited the follow-up period to the first 6 months of life [17,20–22], thus the 'normal' subpopulation values in ex-premature infants are unknown [23].

This study aimed to describe the lymphocyte subpopulations in premature infants over the first 13 months of postnatal life and to determine the impact of antenatal and postnatal exposures and comorbidities.

Manuscript

MATERIALS AND METHODS

This was a planned sub-study of a vaccination trial in which premature infants received the UK primary immunisation schedule and were randomised to 3 different schedules of the 13-valent pneumococcal conjugate vaccine (PCV13) (supplementary table 1). It included all infants enrolled at 5 of the 12 vaccination study sites. The clinical teams identified potentially eligible infants and parents were provided with information by the research teams. Infants were eligible for inclusion if they were born before 35⁺⁰ weeks gestation, were medically fit for vaccination as defined by UK Department of Health guidelines [24] and were between 7 and 12 weeks PNA at the first vaccination dose.

The study was approved by the East of England - Essex regional ethics committee (REC reference 07/HO301.11) and written informed consent was obtained from the infants' parents or legal guardians prior to recruitment. The clinical trial was registered (EudraCT number 2007-007535-23).

Blood sampling and laboratory methods

Each infant had up to 4 blood samples obtained: at 2 months of age, at 5 or 7 months of age (1 month after their final primary vaccinations) and prior to and 1 month after their booster vaccinations at 12 months of age (supplementary table 1). Whole blood (1-2 mL) was collected by venepuncture or capillary sampling into EDTA bottles for lymphocyte subpopulation quantification. All participants were well at the time of phlebotomy with no active infection as assessed by the clinical team. Due to the challenges of obtaining sufficient blood volumes from premature infants, not all babies had samples collected at every time point and, due to the design of the study, fewer infants had blood sampling at 7 months of age than at 5 months of age.

Manuscript

1
2
3
4 Blood samples for lymphocyte analysis were processed within 12 hours of collection in
5
6 the local NHS laboratory and analysed using their routine flow cytometry practice (as
7
8 advised by the manufacturer and local standard operating procedures, table 1).
9

10
11
12 Cell populations measured are shown in supplementary table 2 and supplementary
13
14 figure 1 [22]. Whilst all centres enumerated CD3⁺, CD3⁺CD4⁺ and CD3⁺CD8⁺ cells,
15
16 due to local constraints different markers were used for detection of B cells and NK
17
18 cells. For B cells, 4 centres measured CD19⁺ and one CD20⁺ cells, whilst for NK cells
19
20 4 centres measured CD56⁺ and one CD56⁺CD16⁺ cells. For the purpose of overall
21
22 trends these have been combined into ‘B cells’ and ‘NK cells’.
23
24
25
26
27

28 **Statistical analysis**

29
30 Due to the design of the main vaccination trial there was considerable overlap of ages at
31
32 the final 2 blood samples. Therefore for the purposes of this sub-study, the 12 and 13
33
34 month samples were categorised according to age, rather than their relationship to
35
36 vaccination. A result was considered a ‘12 month’ sample if it was taken between 353
37
38 and 387 days of age, and a “13 month” sample if taken after 387 days of age. If
39
40 participants had more than one sample within each age category only the first was
41
42 included.
43
44

45
46 The data were not all normally distributed and nonparametric tests of statistical
47
48 significance were used. Correlations were calculated using Spearman’s rank correlation
49
50 coefficient. For regression analysis log_e transformed values were used. For B cells and
51
52 NK cell regression analysis, as different cell populations were measured, CD19⁺ and
53
54
55
56
57
58
59
60

Manuscript

1
2
3
4 CD56⁺ were analysed due to the smaller number of CD20⁺ and CD56⁺CD16⁺ results
5
6 (368 and 366 results compared with 49 and 46 results respectively).
7

8 To assess associations between subpopulations, clinical conditions and comorbidities
9 univariable regression analysis was performed on the 2 month and 5 month results for
10 the following variables: sex, small for gestational age (SGA, defined as birth weight less
11 than the 10th centile for gestation), chronic lung disease (CLD, defined as requiring
12 supplemental oxygen or respiratory support at 28 days of age) and receipt of antenatal
13 steroids. All analyses were adjusted for gestation and study centre. Backwards
14 stepwise multivariable regression was performed for variables with significance in
15 univariable analysis ($p \leq 0.2$).
16
17
18
19
20
21
22
23
24
25

26 All data were analysed using STATA version 13 (Stata Inc).
27
28
29

30 **RESULTS**

31
32 A total of 419 analysable samples were collected from 151 infants. The number of
33 infants contributing 1, 2, 3 or 4 samples was 25, 34, 42 and 50 infants respectively. 26
34 samples were excluded as they were the second sample collected between 353 and 387
35 days of age. The characteristics of the infants are shown in table 2.
36
37
38
39
40
41
42
43

44 **Effect of gestational and postnatal age**

45
46 The lymphocyte subpopulation results for different gestational and postnatal ages are
47 shown in table 3, table 4 and figure 1. Overall, there was an increase in the total
48 lymphocyte count and all measured cell populations over the first 13 months of life.
49
50

51 There was an increase in the percentage of CD3⁺CD8⁺ and NK cells and a decrease in
52
53
54
55
56
57
58
59
60

Manuscript

1
2
3
4 the percentage of CD3⁺CD4⁺ cells with increasing age. The CD4⁺:CD8⁺ ratio
5
6 correlated negatively with age.
7

8
9 At 2 months of age there was a positive correlation between gestation and CD3⁺ count
10 and percentage (r=0.32 and 0.22, p=0.001 and 0.028 respectively), CD3⁺CD4⁺ count
11 and percentage (r=0.46 and 0.41 respectively, p<0.001 for both), and a negative
12 correlation with the proportion of CD3⁺CD8⁺ cells (r=-0.32, p=0.001), resulting in
13 positive correlation between CD4:CD8 ratio and birth gestation (r=0.57, p<0.001).
14

15
16 The impact of gestation was rarely significant (p<0.05) after 2 months of age. The only
17 significant associations were the proportion of B cells at 7 months (r=-0.41, p=0.022),
18 NK proportions at 12 months (r=0.22, p=0.023) and CD3⁺CD8⁺ and B cell proportions
19 at 13 months (r=-0.29 and 0.28, p=0.011 and 0.014 respectively).
20
21

22
23 There were no differences between infant lymphocyte profiles according to
24 randomisation group (data not shown).
25
26
27
28
29

30 31 32 33 34 35 36 37 **Associations between co-morbidities, chronic lung disease, antenatal steroids, and** 38 39 **lymphocyte subpopulations**

40
41 There were negative associations between CLD and CD3⁺ count (fold effect – FE -0.78
42 i.e. 22% reduction in CD3⁺ count if CLD present, 95% CI 0.65-0.94; p=0.011),
43 CD3⁺CD4⁺ count (FE 0.78, 95% CI 0.64-0.95; p=0.016) and CD19⁺ count (FE 0.72,
44 95% CI 0.53-0.98; p=0.037) and between receipt of antenatal steroids and CD3⁺CD4⁺
45 percentage (FE 0.86, 95% CI 0.74-1.00, p=0.047) at 2 months PNA only. Postnatal
46 steroids were rarely administered to infants (4 participants). There was no association
47
48 between SGA and any lymphocyte subpopulation.
49
50
51
52
53
54
55
56
57
58
59
60

Manuscript

1
2
3
4 In multivariable regression the association between CD3⁺CD4⁺ percentage and
5
6 antenatal steroids was no longer apparent. Univariable regression revealed no
7
8 significant associations at 5 months of age.
9

10 11 12 13 **Effect of study centre**

14
15 Centres 1 and 5 had significantly different results from the other centres for the
16
17 following subpopulations: CD3⁺%, CD3⁺CD4⁺% (5 only), CD3⁺CD8⁺% and
18
19 CD3⁺CD8⁺ count (1 only) and CD19⁺% (5 only). In addition, there were significant
20
21 differences between centre 4 and the other centres for CD56⁺% and CD56⁺ count.
22
23 These differences remained despite adjustment for the different gestational age
24
25 distributions at each centre.
26
27
28
29

30 31 **DISCUSSION**

32
33 To our knowledge, this is the largest study of lymphocyte subpopulations in premature
34
35 infants reported to date and provides data up to 13 months of age which may assist
36
37 clinicians in assessing the immune status of infants who were born prematurely. With
38
39 increasing age (either gestational or postnatal), an increase in the numbers of
40
41 lymphocytes in all subpopulations was observed. The degree of increase varied
42
43 between subpopulations, resulting in an overall increase in cytotoxic T cells and NK
44
45 cells as a proportion of the total count and a decrease in the proportion of T helper cells
46
47 over the first year of life.
48
49

50
51 Several studies have reported changes in lymphocyte subpopulations over the first year
52
53 of life in term infants. Comparison with these studies is limited by their broad age
54
55 categories and a focus towards comparison with adult values [4,25,26]. However, the
56
57
58
59
60

Manuscript

1
2
3
4 pattern of changes seen in the preterm infants studied are in keeping with those
5
6 described in term infants [5–8]. However, whilst our data show an increase in NK cells
7
8 over the first year of life, the converse is described in term infants [6,27]. The reason
9
10 for this difference is not clear, but it is worth noting that within our dataset a significant
11
12 rise in NK cells appears to occur after 12 months of age, influencing the overall trend.
13
14

15
16
17 The effect of gestation on subpopulations was most apparent at the earliest samples
18
19 when many of the infants had not yet reached term-equivalent. This is consistent with
20
21 the differences reported between premature and term infants at birth [8,9,13,16] as well
22
23 as in previous preterm infant longitudinal studies [20,22]. Berrington *et al.* reported
24
25 lower total lymphocyte count, T cells, B cells and T helper cells at 2 months of age in
26
27 18 preterm infants compared with term infants; some of these populations (total
28
29 lymphocytes, T cells and T helper cells) remained significantly lower at their final
30
31 sample at 6 months of age [22]. Walker *et al.* demonstrated positive correlations
32
33 between cell count and gestation for all subpopulations up to 12 weeks of age; however,
34
35 possibly due to the small numbers of participants (25 preterm infants), these results did
36
37 not reach statistical significance[20].
38
39
40
41
42

43
44 We found no consistent effect of gestation on the number or proportion of B cells at any
45
46 time point. Berrington *et al.* did report lower B cell counts in premature infants at 2
47
48 months of age, which had resolved by 6 months of age but, similar to our data, Walker
49
50 *et al.* found similar B cell counts across all gestations [20,22].
51
52
53
54
55
56
57
58
59
60

Manuscript

1
2
3
4 Although the absolute numbers of lymphocytes vary significantly with age, the relative
5 proportions of the lymphocyte subsets remain more constant and will thus provide a
6 simpler reference for clinicians. It is important for a reference range to be applicable to
7 the whole population; it should be noted that the infants in our study were clinically
8 well at the time of sampling but a significant proportion had a number of co-morbidities
9 that are commonly associated with prematurity. In addition, the multicentre approach
10 permits results to be more generalisable.
11
12
13
14
15
16
17
18
19
20

21
22 Chronic lung disease was associated with lower CD3⁺, CD3⁺CD4⁺ and CD19⁺ counts.
23
24 A previous study found decreased CD2⁺ and CD3⁺CD4⁺ counts in premature infants
25 with CLD at 3 weeks of age and Pelkonen *et al.* described similar findings in the
26 lymphocyte subpopulations of ex-premature school children which were associated with
27 CLD [17,28]. It may be that CLD per se, or an aspect of its treatment, may result in
28 these immunological findings. An intriguing alternative hypothesis is that these
29 abnormalities of immune function are present before the onset of CLD, predisposing to
30 its development and to the recurrent respiratory infections that such infants are prone to
31 [29]. As infants were first sampled after the diagnosis of CLD had been made it is not
32 possible to ascertain if these abnormalities were present earlier.
33
34
35
36
37
38
39
40
41
42
43

44 Unlike other studies, we did not find any association between antenatal steroids and
45 lymphocyte subpopulations in our cohort. Previous studies analysed cord blood
46 samples and it may be that any significant effect of antenatal steroids had resolved by 2
47 months of age [8,13].
48
49
50
51
52
53
54
55
56
57
58
59
60

Manuscript

LIMITATIONS

Our study has some potential limitations. It was conducted as a sub-study and, as such, there was no opportunity for pre-selecting different blood sampling time-points. Early neonatal blood samples would have allowed a more complete description of the subpopulations from birth to one year of age. Fortunately there is a pre-existing evidence base for cord blood of preterm infants at various gestational ages [8–13].

The constraints of NHS laboratories also meant that the investigation of more refined subpopulations e.g. regulatory T and B cells, and functional studies were not possible.

Additionally, laboratory analysis was performed within the routine clinical framework using different sample preparation and analysis techniques. Accordingly, differences were found between the centres for nearly all subpopulations despite some centres using similar analytical laboratory protocols. Correcting for other possible centre-dependant factors (e.g. gestation) using multiple regression did not eliminate these differences. It is known that a variety of factors can affect the inter-laboratory quantification of absolute lymphocyte subpopulations [30–32] and other multicentre studies have experienced similar inter-centre variation, with testing centre the most significant factor in analysis of differences between cell populations [6]. Studies have negated this challenge by freezing peripheral blood mononuclear cells (PBMCs) and centralising samples prior to analysis; or performing single centre studies on whole blood [5,22].

Unfortunately the volume of blood required to extract PBMCs is prohibitively large in low weight infants. In order to address the inter-centre variation, the testing centre was included within the regression analysis. These factors should be considered when designing future studies.

Manuscript

1
2
3
4
5
6 Families were approached to take part in the study before 3 months of age. Babies that
7
8 were too unstable to be vaccinated at this time were unable to participate. This may
9
10 have reduced the number of patients with complex clinical courses. To minimise this,
11
12 recruitment was stratified by age group to ensure extremely premature infants were
13
14 appropriately represented.
15
16

17
18
19 Finally, this study did not include any term infants and as such direct comparison with
20
21 them is not possible.
22
23

24 25 26 **CONCLUSION**

27
28 This is the largest reported cohort to describe lymphocyte subpopulations in premature
29
30 infants and its longitudinal nature provides reference ranges for the major lymphocyte
31
32 subsets. The effect of gestation on subpopulations is most pronounced in early life (up
33
34 to approximately 6 months postnatal age), corresponding with when infants are most
35
36 vulnerable to infection. This may be compounded in infants with co-morbidities,
37
38 especially chronic lung disease, and further study is required to determine the nature of
39
40 this relationship.
41
42
43
44
45

46 **Acknowledgements**

47 We would like to thank all children who took part in the study as well as their
48
49 parents/guardians. We thank the biomedical scientists who analysed the samples Dr Ian
50
51 Thirkettle, Satbeer Singh, and all the study staff at all the research centres. In addition,
52
53 we would like to thank Pauline Kaye, Deborah Cohen, Teresa Gibbs and all other
54
55 members of the team at Public Health England for their invaluable help and support and
56
57 Pfizer for financially supporting this investigator led study.
58
59
60

56 **Author contributions**

Manuscript

1
2
3
4 A Kent coordinated the study, analysed the data and drafted the manuscript. P Heath
5 and S Ladhani developed the initial protocol. All authors helped with the recruitment of
6 and/or blood sampling from participants, contributed to the manuscript review and
7 revision and approved the final version.
8
9

10 **Conflict of Interest Statements**

11 Andrew J Pollard: AJP has previously conducted studies on behalf of Oxford University
12 funded by vaccine manufacturers but does not receive any personal payments or travel
13 support. AJP chairs the UK Department of Health's (DH) Joint Committee on
14 Vaccination and Immunisation (JCVI); the views expressed in this manuscript do not
15 necessarily reflect the views of JCVI or DH
16
17

18 Matthew D Snape: MDS acts as chief and principal investigators for clinical studies
19 from both non-commercial funding bodies and commercial sponsors (i.e. Novartis
20 Vaccines, GlaxoSmithKline, Sanofi-Pasteur, Sanofi-Pasteur MSD, and Pfizer Vaccines)
21 conducted on behalf of the University of Oxford. MDS also undertakes consultancy and
22 advisory work for several commercial sponsors; any speaking honoraria, travel and
23 accommodation reimbursements are paid to the University of Oxford Department of
24 Paediatrics. MDS does not receive any financial support from vaccine manufacturers.
25

26 Shamez N Ladhani: SLN has conducted studies on behalf of St Georges, University of
27 London funded by vaccine manufacturers but does not receive any personal payments or
28 travel support.

29 Paul T Heath: PTH has conducted studies on behalf of St Georges, University of
30 London funded by vaccine manufacturers but does not receive any personal payments or
31 travel support.

32 Alison Kent, Tim Scorer, Paul Clarke, Karen Few, Stephen Hughes, Anu Varghese and
33 Esse Menson have no conflicts of interests to declare.
34
35
36

37 **Funding source**

38 This study was an investigator initiated study funded by Pfizer Inc. The funder had no
39 input in the conduct of the study, preparation of this manuscript or the decision to
40 publish.
41
42

43 **License for Publication Statement**

44 The Corresponding Author has the right to grant on behalf of all authors and does grant
45 on behalf of all authors, an exclusive licence (or non-exclusive for government
46 employees) on a worldwide basis to the BMJ and co-owners or contracting owning
47 societies (where published by the BMJ on their behalf), and its Licensees to permit this
48 article (if accepted) to be published in Archives of Disease in Childhood and any other
49 BMJ products and to exploit all subsidiary rights, as set out in our licence.
50
51
52
53
54
55
56
57
58
59
60

Manuscript

What is already known on this topic:

- At birth, younger gestation is associated with lower concentrations of CD3⁺, CD4⁺, natural killer (NK) and B cells and increased CD4⁺:CD8⁺ ratios
- Existing reference ranges describe major changes in lymphocyte subpopulation numbers in term infants over the first year of life
- Limited information is available on the normal range of lymphocyte subpopulations in preterm infants after the first few months of life

What this study adds:

- Provides reference ranges for lymphocyte subpopulations in premature infants up to 1 year of age
- Total lymphocyte, CD3⁺, CD4⁺, CD8⁺, B and NK cell counts increase up to 1 year of age but subpopulation proportions are more stable
- The effect of gestation is largest at 2 months of age and chronic lung disease is associated with a reduction in CD3⁺, CD4⁺ and CD19⁺ cells

Manuscript

REFERENCES

- 1 Stoll BJ, Hansen NI, Adams-Chapman I, *et al.* Neurodevelopmental and growth impairment among extremely low-birth-weight infants with neonatal infection. *JAMA* 2004;**292**:2357–65. doi:10.1001/jama.292.19.2357
- 2 Vergnano S, Menson E, Kennea N, *et al.* Neonatal infections in England: the NeonIN surveillance network. *Arch Dis Child Fetal Neonatal Ed* 2011;**96**:F9–14. doi:10.1136/adc.2009.178798
- 3 Stoll BJ, Hansen NI, Bell EF, *et al.* Neonatal outcomes of extremely preterm infants from the NICHD Neonatal Research Network. *Pediatrics* 2010;**126**:443–56. doi:10.1542/peds.2009-2959
- 4 Erkeller-Yuksel FM, Deneys V, Yuksel B, *et al.* Age-related changes in human blood lymphocyte subpopulations. *J Pediatr* 1992;**120**:216–22.
- 5 Van Gent R, van Tilburg CM, Nibbelke EE, *et al.* Refined characterization and reference values of the pediatric T- and B-cell compartments. *Clin Immunol* 2009;**133**:95–107. doi:10.1016/j.clim.2009.05.020
- 6 Shearer WT, Rosenblatt HM, Gelman RS, *et al.* Lymphocyte subsets in healthy children from birth through 18 years of age : The Pediatric AIDS Clinical Trials Group P1009 study. *J Allergy Clin Immunol* 2003;**112**:973–80. doi:10.1067/mai.2003.1778
- 7 Christensen RD, Baer VL, Gordon P V, *et al.* Reference ranges for lymphocyte counts of neonates: associations between abnormal counts and outcomes. *Pediatrics* 2012;**129**:e1165–72. doi:10.1542/peds.2011-2661
- 8 Correa-Rocha R, Pérez A, Lorente R, *et al.* Preterm neonates show marked leukopenia and lymphopenia that are associated with increased regulatory T-cell values and diminished IL-7. *Pediatr Res* 2012;**71**:590–7. doi:10.1038/pr.2012.6
- 9 Pérez A, Gurbindo MD, Resino S, *et al.* NK cell increase in neonates from the preterm to the full-term period of gestation. *Neonatology* 2007;**92**:158–63. doi:10.1159/000101567
- 10 Juretić E, Uzarević B, Petrovecki M, *et al.* Two-color flow cytometric analysis of preterm and term newborn lymphocytes. *Immunobiology* 2000;**202**:421–8. doi:10.1016/S0171-2985(00)80101-1
- 11 Kotiranta-Ainamo A, Apajasalo M, Pohjavuori M, *et al.* Mononuclear cell subpopulations in preterm and full-term neonates: independent effects of gestational age, neonatal infection, maternal pre-eclampsia, maternal betamethason therapy, and mode of delivery. *Clin Exp Immunol* 1999;**115**:309–14.
- 12 Thomas RM, Linch DC. Identification of lymphocyte subsets in the newborn using a variety of monoclonal antibodies. *Arch Dis Child* 1983;**58**:34–8.

Manuscript

- 1
2
3 13 Kavelaars A, van der Pompe G, Bakker JM, *et al.* Altered immune function in human
4 newborns after prenatal administration of betamethasone: enhanced natural killer cell
5 activity and decreased T cell proliferation in cord blood. *Pediatr Res* 1999;**45**:306–12.
6 doi:10.1203/00006450-199903000-00003
7
- 8
9 14 Quinello C, Silveira-Lessa a L, Ceccon MEJR, *et al.* Phenotypic differences in
10 leucocyte populations among healthy preterm and full-term newborns. *Scand J*
11 *Immunol* 2014;**80**:57–70. doi:10.1111/sji.12183
12
- 13 15 Duijts L, Bakker-Jonges LE, Labout JAM, *et al.* Fetal growth influences lymphocyte
14 subset counts at birth: the Generation R Study. *Neonatology* 2009;**95**:149–56.
15 doi:10.1159/000153099
16
- 17 16 Chabra S, Cottrill C, Rayens MK, *et al.* Lymphocyte subsets in cord blood of preterm
18 infants: effect of antenatal steroids. *Biol Neonate* 1998;**74**:200–7.
19
- 20 17 Sériès IM, Pichette J, Carrier C, *et al.* Quantitative analysis of T and B cell subsets in
21 healthy and sick premature infants. *Early Hum Dev* 1991;**26**:143–54.
22
- 23 18 Kavelaars A, Zijlstral J, Bakker J, *et al.* Increased dexamethasone sensitivity of
24 neonatal leukocytes : different mechanisms of glucocorticoid inhibition of T cell
25 proliferation in adult and neonatal cells. *Eur J Immunol* 1995;**25**:1346–51.
26
- 27 19 Kavelaars A, Cats B, Visser GH, *et al.* Ontogeny of the Response of Human Peripheral
28 Blood T Cells to Glucocorticoids. *Brain, Behav Immun* 1996;**29**:288–97.
29
- 30 20 Walker JC, Smolders M a JC, Gemen EF a, *et al.* Development of lymphocyte
31 subpopulations in preterm infants. *Scand J Immunol* 2011;**73**:53–8.
32 doi:10.1111/j.1365-3083.2010.02473.x
33
- 34 21 Bussel JB, Cunningham-Rundles S, LaGamma EF, *et al.* Analysis of lymphocyte
35 proliferative response subpopulations in very low birth weight infants and during the
36 first 8 weeks of life. *Pediatr Res* 1988;**23**:457–62. doi:10.1203/00006450-198805000-
37 00003
38
- 39 22 Berrington JE, Barge D, Fenton AC, *et al.* Lymphocyte subsets in term and
40 significantly preterm UK infants in the first year of life analysed by single platform
41 flow cytometry. *Clin Exp Immunol* 2005;**140**:289–92. doi:10.1111/j.1365-
42 2249.2005.02767.x
43
- 44 23 Ward CE, Baptist AP. Challenges of newborn severe combined immunodeficiency
45 screening among premature infants. *Pediatrics* 2013;**131**:e1298–302.
46 doi:10.1542/peds.2012-1921
47
- 48 24 Department of Health. Contraindications and special considerations (Chapter 6).
49 Immunisation against Infectious Disease: The Green Book.
50 2006.[https://www.gov.uk/government/collections/immunisation-against-infectious-](https://www.gov.uk/government/collections/immunisation-against-infectious-disease-the-green-book)
51 [disease-the-green-book](https://www.gov.uk/government/collections/immunisation-against-infectious-disease-the-green-book)
52
53
54
55
56
57
58
59
60

Manuscript

- 1
2
3 25 Yanase Y, Tango T, Okumura KO, *et al.* Lymphocyte Subsets Identified by
4 Monoclonal Antibodies in Healthy Children. *Pediatr Res* 1986;**20**:1147–51.
5
6 26 Tosato F, Bucciol G, Pantano G, *et al.* Lymphocytes subsets reference values in
7 childhood. *Cytometry A* 2015;**87**:81–5. doi:10.1002/cyto.a.22520
8
9
10 27 De Vries E, de Bruin-Versteeg S, Comans-Bitter WM, *et al.* Longitudinal survey of
11 lymphocyte subpopulations in the first year of life. *Pediatr Res* 2000;**47**:528–37.
12
13 28 Pelkonen AS, Suomalainen H, Hallman M, *et al.* Peripheral blood lymphocyte
14 subpopulations in schoolchildren born very preterm. *Arch Dis Child Fetal Neonatal Ed*
15 1999;**81**:F188–93.
16
17 29 Greenough A. Bronchopulmonary dysplasia--long term follow up. *Paediatr Respir Rev*
18 2006;**7 Suppl 1**:S189–91. doi:10.1016/j.prrv.2006.04.206
19
20
21 30 Levering WHBM, van Wieringen WN, Kraan J, *et al.* Flow cytometric lymphocyte
22 subset enumeration: 10 years of external quality assessment in the Benelux countries.
23 *Cytometry B Clin Cytom* 2008;**74**:79–90. doi:10.1002/cyto.b.20370
24
25 31 Lambert C, Cristina I, Christian G. Enumeration of peripheral lymphocyte subsets
26 using 6 vs. 4 color staining: a clinical evaluation of a new flowcytometer. *Cytometry B*
27 *Clin Cytom* 2006;**70**:29–38. doi:10.1002/cyto.b.20072
28
29
30 32 Dos Santos AP, Bertho AL, Martins R de M, *et al.* The sample processing time
31 interval as an influential factor in flow cytometry analysis of lymphocyte subsets. *Mem*
32 *Inst Oswaldo Cruz* 2007;**102**:117–20.
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1: Flowcytometer methodology by centre.

BC: Beckman Coulter Inc, Miami, USA; BD: Becton Dickinson Inc, San Jose, USA; Siemens AG Erlangen, Germany. FITC: Fluorescein isothiocyanate, PerCP-Cy5.5: peridinin chlorophyll protein cyanin 5.5, APC: allophycocyanin, PE: phycoerythrin.

Table 2: Participant characteristics by gestational age at birth.

Median (range) or n (%).

^aSignificant difference between groups (p<0.05).

Table 3: Lymphocyte subpopulations by postnatal and gestational age at birth.

Absolute count x10⁹/L. Median (5-95th centile). Lymphocytes: CD45⁺. B cells: CD19⁺, CD20⁺. NK cells: CD56⁺, CD56⁺CD16⁺. p value calculated using Spearman rank correlation coefficient for postnatal age.

Table 4: Lymphocyte subpopulations by postnatal and gestational age at birth. Percentage of total lymphocyte count. Median % (5-95th centile). Lymphocytes: CD45⁺. B cells: CD19⁺, CD20⁺. NK cells: CD56⁺, CD56⁺CD16⁺. p value calculated using Spearman rank correlation coefficient for postnatal age.

Figure 1: Lymphocyte subpopulations at different gestational and postnatal ages (median percentage). A: Birth gestation <28 weeks, B: Birth gestation 28⁺⁰-31⁺⁶ weeks, C: Birth gestation: 32⁺⁰ – 34⁺⁶ weeks

Table 1

Centre	Sample preparation	Analyser	Analysis Software	Lymphocyte count
1	BD FACS lyse BD individual monoclonal antibody reagent	BD FACScalibur	MultiSET	Siemens Advia 2120
2	BD multitest 6-colour TBNK reagent (CD3 ⁺ FITC / CD16 ⁺ & CD56 ⁺ PE / CD4 ⁺ 5 PerCP-C TM 5.5 / CD4 ⁺ PE-Cy TM 7 / CD19 / CD8 ⁺ APC-Cy7) With BD Trucount tubes	BD FACScanto II	BD FACScanto v2.4	Sysmex XE2100
3	BC CYTO-STAT tetraCHROME reagent (CD4 ⁺ 5-FITC/CD4 ⁺ -RDI/CD8 ⁺ -ECD/CD3 ⁺ -PC5)	BC FC500	TetraCXP	BC LH750
4	BC CYTO-STAT tetraCHROME reagent (CD4 ⁺ 5-FITC/CD4 ⁺ -RDI/CD8 ⁺ -ECD/CD3 ⁺ -PC5)	BC FC500	TetraCXP	BC DxH
5	BD multitest CD3 ⁺ /CD8 ⁺ /CD4 ⁺ 5/CD4 ⁺ BD multitest CD3 ⁺ /CD16 ⁺ CD56 ⁺ /CD4 ⁺ 5/CD19 ⁺ With BD Trucount tubes	BD FACScanto II	BD FACScanto v2.4	NA (single platform)

Table 2

	<28 weeks	28-31+6 weeks	32+0-34+6 weeks
N	32	64	55
Gestation (weeks)	26.5 (23.3-27.9)	29.7 (28-31.6)	33.4 (32-34.9)
Birth weight (g) ^a	840 (490-1398)	1298 (521-2070)	1895 (1335-2680)
Sex – male	19 (59)	27 (42)	29 (53)
SGA	10 (31)	13 (20)	10 (18)
CLD*	31 (97)	21 (33)	1 (2)
Antenatal steroids	30 (94)	53 (83)	44 (80)
Weight at first blood ^b	1900 (1070-2764)	2280 (845-3670)	3130 (2000-4620)
Blood A samples (n)	24	48	33
Blood A age (days) ^a	64 (54-83)	61 (48-84)	60 (49-86)
Blood B samples – 5m (n)	15	30	23
Blood B age – 5m (days)	159 (135-175)	158 (135-180)	149 (132-199)
Blood B samples – 7m (n)	11	11	16
Blood B age – 7m (days) ^a	207 (196-241)	206 (187-215)	195 (179-224)
Blood C samples – 12m (n)	20	48	37
Blood C age – 12m (days)	365 (353-387)	364 (354-385)	368 (353-387)
Blood D samples – 13m (n)	17	36	24
Blood D age – 13m (days)	399 (389-439)	401 (388-443)	407 (389-492)

Table 3

Population	Gestation (weeks)	2 months	5 months	7 months	12 months	13 months	p
Total Lymphocytes	<28	4.55 (3.30-6.70)	5.85 (2.70-10.94)	6.20 (4.60-7.80)	6.45 (2.49-8.96)	6.22 (2.12-11.90)	0.003
	28-31+6	4.85 (2.95-8.50)	5.58 (2.20-9.60)	5.70 (4.36-8.36)	5.73 (3.70-9.93)	6.37 (3.01-11.65)	0.001
	32+0-34+6	5.29 (3.25-9.10)	6.00 (3.00-7.40)	5.68 (3.40-11.10)	5.88 (2.60-10.00)	5.91 (2.80-10.90)	0.19
	All	4.90 (3.10-8.30)	5.75 (2.80-9.52)	5.77 (3.40-10.60)	5.88 (2.62-9.55)	6.21 (2.80-11.65)	<0.001
CD3 ⁺	<28	2.76 (1.78-3.89)	3.34 (1.76-6.92)	3.55 (2.74-5.46)	4.50 (1.50-6.92)	3.87 (1.14-7.45)	<0.001
	28-31+6	3.13 (1.90-4.81)	3.45 (1.22-6.90)	3.66 (2.81-5.92)	3.75 (1.88-7.27)	4.30 (1.89-6.58)	<0.001
	32+0-34+6	3.40 (1.18-7.40)	3.40 (2.05-5.18)	3.82 (2.01-7.88)	3.36 (1.55-8.08)	3.57 (1.64-6.77)	0.58
	All	3.13 (1.78-5.48)	3.40 (1.63-6.70)	3.66 (2.45-6.51)	3.82 (1.88-7.07)	3.81 (1.76-7.40)	<0.001
CD3 ⁺ CD4 ⁺	<28	1.65 (1.20-2.65)	2.29 (1.16-4.42)	2.50 (1.81-3.78)	2.85 (0.95-5.03)	2.58 (0.65-5.12)	0.001
	28-31+6	2.17 (1.30-3.70)	2.59 (0.99-4.99)	2.65 (1.98-3.85)	2.47 (1.23-5.12)	2.81 (1.16-4.14)	0.011
	32+0-34+6	2.46 (0.90-6.28)	2.45 (1.42-4.22)	2.44 (1.29-5.88)	2.07 (1.17-5.50)	2.26 (0.70-4.75)	0.23
	All	2.16 (1.22-4.14)	2.45 (1.17-4.74)	2.51 (1.61-4.93)	2.47 (1.23-5.12)	2.54 (1.04-4.81)	0.013
CD3 ⁺ CD8 ⁺	<28	0.94 (0.40-1.34)	1.10 (0.54-3.54)	1.09 (0.79-1.59)	1.42 (0.50-1.98)	1.31 (0.47-3.25)	<0.001

	28-31+6	0.76 (0.47-1.19)	0.85 (0.21-2.03)	1.06 (0.51-2.05)	1.02 (0.52-2.05)	1.21 (0.48-2.39)	<0.001
	32+0-34+6	0.88 (0.28-1.71)	0.76 (0.36-1.38)	1.01 (0.36-2.05)	1.09 (0.28-2.41)	0.83 (0.53-2.24)	0.021
	All	0.84 (0.44-1.33)	0.86 (0.34-1.85)	1.04 (0.51-2.05)	1.09 (0.45-2.07)	1.19 (0.48-2.50)	<0.001
B cells	<28	1.31 (0.65-3.03)	1.45 (0.67-3.34)	1.99 (0.98-3.26)	1.63 (0.62-3.02)	1.57 (0.61-3.65)	0.33
	28-31+6	1.29 (0.52-3.66)	1.66 (0.48-3.31)	1.60 (0.80-2.52)	1.55 (0.59-2.80)	1.61 (0.38-4.52)	0.14
	32+0-34+6	1.58 (0.32-2.32)	1.33 (0.50-2.65)	1.64 (0.54-3.50)	1.58 (0.52-2.73)	1.81 (0.74-3.17)	0.014
	All	1.32 (0.52-3.00)	1.45 (0.50-3.02)	1.71 (0.65-3.26)	1.57 (0.59-2.80)	1.66 (0.46-3.65)	0.006
NK cells	<28	0.26 (0.04-0.59)	0.27 (0.02-0.66)	0.30 (0.05-1.47)	0.22 (0.10-1.42)	0.46 (0.09-1.31)	0.008
	28-31+6	0.23 (0.06-0.60)	0.23 (0.04-1.42)	0.23 (0.05-0.66)	0.28 (0.08-0.75)	0.38 (0.12-1.57)	0.001
	32+0-34+6	0.25 (0.04-0.82)	0.22 (0.06-0.50)	0.26 (0.03-1.65)	0.35 (0.08-1.16)	0.41 (0.13-1.51)	<0.001
	All	0.25 (0.05-0.68)	0.23 (0.04-0.66)	0.28 (0.04-1.47)	0.29 (0.08-0.90)	0.39 (0.12-1.51)	<0.001

Table 4

Population	Gestation (weeks)	2 months	5 months	7 months	12 months	13 months	p
CD3⁺	<28	59.0 (38.0-79.0)	65.0 (52.0-77.0)	60.4 (47.0-73.0)	67.4 (45.0-79.5)	63.7 (50.0-80.0)	0.04
	28-31+6	64.1 (47.0-82.0)	65.0 (42.0-86.3)	62.0 (59.0-70.8)	67.0 (51.0-80.6)	65.2 (46.1-89.0)	0.42
	32+0-34+6	65.5 (53.0-86.0)	66.4 (46.0-81.0)	67.5 (42.0-79.0)	63.0 (52.0-78.0)	60.0 (46.0-71.0)	0.026
	All	64.0 (45.0-82.0)	65.0 (46.0-83.0)	62.1 (47.0-74.0)	65.0 (52.0-80.0)	63.1 (46.1-82.0)	0.86
CD3⁺CD4⁺	<28	39.1 (24.0-54.0)	44.0 (29.0-64.0)	40.6 (31.8-52.0)	43.6 (27.0-57.0)	42.0 (25.0-54.0)	0.30
	28-31+6	46.5 (31.2-63.0)	49.0 (29.0-64.8)	43.0 (37.0-56.4)	47.4 (36.0-57.3)	45.0 (27.6-62.0)	0.13
	32+0-34+6	50.5 (36.0-69.0)	51.0 (35.0-68.0)	45.0 (32.0-56.0)	42.0 (26.0-55.0)	41.5 (16.0-56.0)	<0.001
	All	46.0 (26.0-63.0)	49.0 (33.0-67.0)	43.0 (32.0-56.0)	44.0 (32.0-57.0)	43.0 (21.0-56.2)	0.002
CD3⁺CD8⁺	<28	19.1 (12.0-32.0)	19.0 (15.0-31.0)	17.8 (14.0-23.0)	20.1 (13.8-28.6)	22.5 (15.0-31.0)	0.11
	28-31+6	15.2 (10.0-26.0)	16.0 (9.0-27.0)	17.0 (11.0-27.0)	17.7 (11.7-26.0)	19.0 (12.0-30.0)	<0.001
	32+0-34+6	15.8 (10.0-22.0)	15.5 (9.0-25.0)	17.5 (7.5-31.0)	18.0 (11.0-28.0)	17.0 (12.0-28.0)	0.032
	All	16.0 (10.0-26.0)	16.0 (9.0-26.0)	17.4 (11.0-30.0)	18.0 (12.0-28.0)	19.0 (12.0-31.0)	<0.001
B cells	<28	27.5 (17.0-48.0)	26.6 (19.0-38.0)	31.4 (17.2-42.0)	24.4 (12.5-38.0)	24.1 (10.0-42.8)	0.24
	28-31+6	27.8 (15.3-43.0)	29.1 (11.0-48.0)	28.0 (18.3-35.0)	26.4 (14.6-42.0)	26.4 (7.0-38.6)	0.26
	32+0-34+6	27.6 (10.0-35.0)	24.0 (8.1-45.0)	23.6 (16.0-37.7)	28.5 (17.0-35.0)	30.1 (18.1-43.0)	0.07
	All	27.8	27.0	27.8	26.9	27.2	0.84

		(15.0-43.0)	(11.0-45.0)	(17.2-37.7)	(15.0-39.5)	(10.1-42.8)	
NK cells	<28	5.2 (1.0-12.2)	5.0 (0.7-7.0)	5.0 (1.0-21.3)	4.4 (1.5-20.6)	7.7 (3.0-25.9)	0.12
	28-31+6	5.0 (1.0-10.8)	4.0 (1.0-15.3)	4.0 (1.0-7.9)	5.0 (2.0-11.2)	6.9 (2.3-16.6)	0.07
	32+0-34+6	4.0 (1.0-14.5)	4.0 (1.0-10.0)	4.9 (0.3-34.6)	5.7 (2.0-25.1)	8.1 (2.0-24.1)	<0.001
	All	0.25 (0.05-0.68)	0.23 (0.04-0.66)	0.28 (0.04-1.47)	0.3 (0.1-0.9)	0.4 (0.1-1.5)	0.001
CD4⁺:CD8⁺	<28	1.93 (1.27-2.85)	2.23 (0.96-4.02)	2.36 (1.69-3.00)	2.07 (1.37-3.49)	2.1 (0.8-3.0)	0.68
	28-31+6	3.00 (1.54-5.07)	3.38 (1.76-5.22)	2.61 (1.52-4.84)	2.60 (1.51-4.14)	2.5 (1.3-3.9)	<0.001
	32+0-34+6	3.11 (2.33-5.00)	3.34 (1.79-5.58)	2.78 (1.09-4.55)	2.49 (0.93-4.23)	2.4 (0.8-4.7)	<0.001
	All	2.77 (1.54-4.90)	3.05 (1.76-5.57)	2.53 (1.27-4.57)	2.46 (1.40-4.14)	2.35 (0.79-4.05)	<0.001




Figure 1: Lymphocyte subpopulations at different gestational and postnatal ages (median percentage). A: Birth gestation <28 weeks, B: Birth gestation 28+0-31+6 weeks, C: Birth gestation: 32+0 – 34+6 weeks
254x184mm (300 x 300 DPI)

Review Only

Supplementary figures

Supplementary table 1: Study design. Pediacel (Sanofi Pasteur MSD), Prevenar13 (Pfizer Inc), Menjugate (Novartis Diagnostics and Vaccine, Siena, Italy), Priorix (GlaxoSmithKline Ltd) and Menitorix (GlaxoSmithKline Ltd)

Supp Table 1

Approx. age (months)	2	3	4	5	6	7	12	13
Group 1	Blood sample Pediacel TM Prevenar13 TM	Pediacel TM Menjugate TM	Pediacel TM Menjugate TM Prevenar13 TM	Blood sample			Blood sample Priorix TM Menitorix TM Prevenar13 TM	Blood sample
Group 2	Blood sample Pediacel TM Prevenar13 TM	Pediacel TM Menjugate TM Prevenar13 TM	Pediacel TM Menjugate TM Prevenar13 TM	Blood sample			Blood sample Priorix TM Menitorix TM Prevenar13 TM	Blood sample
Group 3	Blood sample Pediacel TM Prevenar13 TM	Pediacel TM Menjugate TM	Pediacel TM Menjugate TM Prevenar13 TM		Prevenar13 TM	Blood sample	Blood sample Priorix TM Menitorix TM Prevenar13 TM	Blood sample

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Supplementary table 2: Lymphocyte subpopulations measured

Supp Table 2

Cell population	CD Marker
Total lymphocyte count	Side scatter and CD45
T cell	CD3
T helper cell	CD3/CD4
Cytotoxic T cell	CD3/CD8
Natural killer cell	CD56 and/or CD16
B cell	CD19 or CD20


Confidential: For Review Only

Supplementary figure 1

Lymphocytes selected (CD45 bright, low side scatter)

Confidential: For Review Only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



33x33mm (300 x 300 DPI)

Review Only